A PPARα agonist (EC50s = 18 and 30 μM for mouse and human receptors, respectively, in a transactivation assay); selective for PPARα over PPARγ (EC50s = 300 and 200 μM for mouse and human receptors, respectively) and lacks activity at mouse and human PPARδ at 100 μM; reduces plasma levels of triglycerides, C-reactive protein, and MDA in mice with fructose-induced hypertriglycemia from 50-100 mg/kg; decreases cisplatin-induced glomerular and tubular atrophy and necrosis in rat kidney at 100 mg/kg; reduces the number of 4-NQO-induced pulmonary lesions in lung in TSOD mice